Literature DB >> 8429236

Eosinophil migration in atopic dermatitis. I: Increased migratory responses to N-formyl-methionyl-leucyl-phenylalanine, neutrophil-activating factor, platelet-activating factor, and platelet factor 4.

P L Bruijnzeel1, P H Kuijper, S Rihs, S Betz, R A Warringa, L Koenderman.   

Abstract

Eosinophil granular protein deposits have been demonstrated in lesional atopic dermatitis skin. This suggests active tissue infiltration of eosinophils. To find an explanation for the tissue influx of eosinophils, eosinophil migration was studied in vitro by means of a microchemotaxis assay. Eosinophils from the circulation of patients with atopic dermatitis showed an altered capacity to respond to chemotactic stimuli in vitro compared with eosinophils from healthy donors. Eosinophils from patients with atopic dermatitis had significantly increased migratory responses toward dose ranges of N-formyl-methionyl-leucyl-phenylalanine, neutrophil-activating factor, platelet-activating factor, and platelet factor 4. Eosinophils from normal individuals did not respond to N-formyl-methionyl-leucyl-phenylalanine and neutrophil-activating factor and responded only slightly to platelet factor 4. The migratory responses toward tumor necrosis factor-alpha and complement factor C5a were identical in both groups. Interleukin-5, an eosinophil-selective cytokine, is a strong modulator of the migratory responses to these chemotaxins in eosinophils from normal donors. A migratory response toward N-formyl-methionyl-leucyl-phenylalanine and neutrophil-activating factor was induced by interleukin-5, whereas the migratory response toward platelet-activating factor and platelet factor 4 was markedly potentiated. In contrast, the response to complement fragment C5a was only slightly influenced. Our findings indicate that the increased migratory responsiveness of eosinophils from patients with atopic dermatitis to various chemotaxins reflects in vivo "priming" of eosinophils, presumably by circulating cytokines such as interleukin-5. This in vivo "priming" is not optimal because it can be further potentiated by renewed contact with interleukin-5.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429236     DOI: 10.1111/1523-1747.ep12462781

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

1.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

2.  Enhanced platelet activation in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Marek Nowakowski; Barbara Rogala
Journal:  Inflammation       Date:  2004-10       Impact factor: 4.092

Review 3.  Platelets in patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

Review 4.  Platelet activation during allergic inflammation.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2007-10       Impact factor: 4.092

5.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

Review 6.  A new dawn for eosinophils in the tumour microenvironment.

Authors:  Sharon Grisaru-Tal; Michal Itan; Amy D Klion; Ariel Munitz
Journal:  Nat Rev Cancer       Date:  2020-07-16       Impact factor: 60.716

7.  Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis.

Authors:  D L Bratton; Q Hamid; M Boguniewicz; D E Doherty; J M Kailey; D Y Leung
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

8.  Biological activities of C3 beta c, a novel neutrophil chemoattractant derived from the beta-chain of rat complement C3.

Authors:  H Nakagawa; Y Sunada; Y Ando
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

9.  Role of cyclic GMP on inhibition by nitric oxide donors of human eosinophil chemotaxis in vitro.

Authors:  Sara M Thomazzi; Juliana Moreira; Sisi Marcondes; Gilberto De Nucci; Edson Antunes
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 10.  Platelet-Eosinophil Interactions As a Potential Therapeutic Target in Allergic Inflammation and Asthma.

Authors:  Sajeel A Shah; Clive P Page; Simon C Pitchford
Journal:  Front Med (Lausanne)       Date:  2017-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.